tirzepatide breastfeeding data Is Safe While Breastfeeding? FDA Guidance & Alternatives Tirzepatide and breastfeeding: New research
Description
Our providers are licensed in 34 states this makes sure we can treat you
The SURMOUNT-1 data shows that weight loss continues in a roughly linear fashion through week 40, with the rate slowing gradually after that
Dose escalation needs clinical guidance
Expect 1-2 pounds per week on average if adherence is good, though its not always linear
Rapid weight loss exceeding 1-2% of body weight per week
